Calliditas Therapeutics AB (Calliditas Therapeutics AB) FCF Margin % : 5.06% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Calliditas Therapeutics AB's Free Cash Flow for the three months ended in Dec. 2023 was $2.23 Mil. Calliditas Therapeutics AB's Revenue for the three months ended in Dec. 2023 was $44.02 Mil. Therefore, Calliditas Therapeutics AB's FCF Margin % for the quarter that ended in Dec. 2023 was 5.06%.

As of today, Calliditas Therapeutics AB's current FCF Yield % is -3.70%.

The historical rank and industry rank for Calliditas Therapeutics AB's FCF Margin % or its related term are showing as below:

CALT' s FCF Margin % Range Over the Past 10 Years
Min: -35375.4 Med: -47.18 Max: -19.4
Current: -19.4

During the past 9 years, the highest FCF Margin % of Calliditas Therapeutics AB was -19.40%. The lowest was -35375.40%. And the median was -47.18%.

CALT's FCF Margin % is ranked better than
69.35% of 1031 companies
in the Biotechnology industry
Industry Median: -148.24 vs CALT: -19.40

Calliditas Therapeutics AB FCF Margin % Historical Data

The historical data trend for Calliditas Therapeutics AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB FCF Margin % Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-47.18

-35,209.52

-211.14

-39.09

-36.01

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-47.96	53.62	-60.52	-21.23	5.06

Competitive Comparison of Calliditas Therapeutics AB's FCF Margin %

For the Biotechnology subindustry, Calliditas Therapeutics AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calliditas Therapeutics AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's FCF Margin % falls into.

Calliditas Therapeutics AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Calliditas Therapeutics AB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-42.374	/	117.658
	=	-36.01 %

Calliditas Therapeutics AB's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	2.227	/	44.022
	=	5.06 %

Calliditas Therapeutics AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.